Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
failed trials
Biotech
Ocuphire's diabetic eye drug misses phase 2 primary endpoint
Ocuphire Pharma’s diabetic retinopathy candidate missed the primary endpoint of a phase 2 trial, sending the company’s shares down over 25%.
James Waldron
Jan 26, 2023 8:32am
J&J packs up HIV vaccine after failing phase 3 trial
Jan 18, 2023 10:44am
Irlab's Ipsen-partnered Parkinson's drug flunks phase 2 trial
Jan 18, 2023 10:08am
Oramed’s oral insulin flunks phase 3 diabetes test
Jan 12, 2023 6:30am
Merck bails on NGM eye disease collab in wake of trial failure
Dec 21, 2022 9:09am
'Uninterpretable' phase 3 results stymie ContraFect
Dec 20, 2022 1:18pm
